Androgen Therapy Linked to Periodontal Disease
Four out of five androgen-deprived prostate cancer patients have periodontal disease
THURSDAY, March 15 (HealthDay News) -- Men with prostate cancer treated with androgen deprivation therapy have a higher risk of periodontal disease than patients not undergoing the therapy, researchers report in the March issue of the Journal of Urology.
Pouran Famili, D.M.D., Ph.D., of the University of Pittsburgh, and colleagues compared periodontal disease in relation to bone mineral density in 27 prostate cancer patients who were not on androgen deprivation therapy and 41 prostate cancer patients undergoing the treatment.
The researchers found that 80.5 percent of the androgen-deprived prostate cancer patients had periodontal disease, versus 3.7 percent of those not on androgen deprivation, for an odds ratio of 3.33. Non-deprived patients had lower plaque scores and markedly smaller probing depth than androgen-deprived patients.
However, the researchers found no connection between periodontal disease and bone mineral density in the 81 men who underwent full bone mineral density checks.
"Men with prostate cancer undergoing androgen deprivation therapy were more likely to have periodontal disease than men not on androgen deprivation therapy," the authors write. "If confirmed in larger studies, this observation could have important public health implications, given the increasing use of androgen deprivation therapy to treat prostate cancer."